An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck
This is a study of Nivolumab in combination with experimental medication BMS-986205 compared to the standard of care EXTREME regimen in head and neck cancer that has come back after initial treatment, or is widespread when first diagnosed.
Head and Neck Cancer
BIOLOGICAL: Nivolumab|DRUG: BMS-986205|BIOLOGICAL: Cetuximab|DRUG: Cisplatin|DRUG: Carboplatin|DRUG: Fluorouracil
Progression-free survival (PFS) as determined by Blinded Independent Central Review (BICR) using RECIST 1.1, Approximately 2 years|Overall survival (OS), Approximately 40 months|Objective response rate (ORR) determined by BICR using RECIST 1.1, Approximately 2 years
Number of adverse events (AE), Approximately 2 years|Number of serious adverse events (SAE), Approximately 2 years|Time to meaningful symptomatic deterioration (TTSD), Approximately 2 years
This is a study of Nivolumab in combination with experimental medication BMS-986205 compared to the standard of care EXTREME regimen in head and neck cancer that has come back after initial treatment, or is widespread when first diagnosed.